Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

详细信息    查看全文

• 作者：Brian I. Rini ; David I. Quinn ; Michael Baum ; Laura S. Wood…
• 关键词：Renal cell carcinoma ; Axitinib ; Sorafenib ; Hypertension ; Blood pressure
• 刊名：Targeted Oncology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：10
• 期：1
• 页码：45-53
• 全文大小：256 KB
• 参考文献：1. Hu-Lowe, DD, Zou, HY, Grazzini, ML, Hallin, ME, Wickman, GR, Amundson, K, Chen, JH, Rewolinski, DA, Yamazaki, S, Wu, EY, McTigue, MA, Murray, BW, Kania, RS, O'Connor, P, Shalinsky, DR, Bender, SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14: pp. 7272-7283 CrossRef
  2. Rini, BI, Escudier, B, Tomczak, P, Kaprin, A, Szczylik, C, Hutson, TE, Michaelson, MD, Gorbunova, VA, Gore, ME, Rusakov, IG, Negrier, S, Ou, YC, Castellano, D, Lim, HY, Uemura, H, Tarazi, J, Cella, D, Chen, C, Rosbrook, B, Kim, S, Motzer, RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: pp. 1931-1939 CrossRef
  3. Cohen, RB, Oudard, S (2012) Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs 30: pp. 2066-2079 CrossRef
  4. Bhargava, P (2009) VEGF kinase inhibitors: how do they cause hypertension?. Am J Physiol Regul Integr Comp Physiol 297: pp. R1-R5 CrossRef
  5. Jain, M, Townsend, RR (2007) Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 9: pp. 320-328 CrossRef
  6. Robinson, ES, Khankin, EV, Karumanchi, SA, Humphreys, BD (2010) Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 30: pp. 591-601 CrossRef
  7. Launay-Vacher, V, Deray, G (2009) Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 20: pp. 81-82 CrossRef
  8. Escudier, B, Pluzanska, A, Koralewski, P, Ravaud, A, Bracarda, S, Szczylik, C, Chevreau, C, Filipek, M, Melichar, B, Bajetta, E, Gorbunova, V, Bay, JO, Bodrogi, I, Jagiello-Gruszfeld, A, Moore, N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: pp. 2103-2111 CrossRef
  9. Motzer, RJ, Hutson, TE, Tomczak, P, Michaelson, MD, Bukowski, RM, Rixe, O, Oudard, S, Negrier, S, Szczylik, C, Kim, ST, Chen, I, Bycott, PW, Baum, CM, Figlin, RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: pp. 115-124 CrossRef
  10. Escudier, B, Eisen, T, Stadler, WM, Szczylik, C, Oudard, S, Siebels, M, Negrier, S, Chevreau, C, Solska, E, Desai, AA, Rolland, F, Demkow, T, Hutson, TE, Gore, M, Freeman, S, Schwartz, B, Shan, M, Simantov, R, Bukowski, RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: pp. 125-134 CrossRef
  11. Sternberg, CN, Davis, ID, Mardiak, J, Szczylik, C, Lee, E, Wagstaff, J, Barrios, CH, Salman, P, Gladkov, OA, Kavina, A, Zarba, JJ, Chen, M, McCann, L, Pandite, L, Roychowdhury, DF, Hawkins, RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: pp. 1061-1068 CrossRef
  12. Robinson, ES, Khankin, EV, Choueiri, TK, Dhawan, MS, Rogers, MJ, Karumanchi, SA, Humphreys, BD (2010) Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 56: pp. 1131-1136 CrossRef
  13. Facemire, CS, Nixon, AB, Griffiths, R, Hurwitz, H, Coffman, TM (2009) Vascular endothelial growth factor receptor
• 刊物主题：Oncology; Biomedicine general;
• 出版者：Springer Paris
• ISSN：1776-260X

文摘

Inhibitors of the vascular endothelial growth factor (VEGF) pathway frequently induce hypertension when used to treat patients with advanced renal cell carcinoma (RCC). This analysis characterizes hypertension and hypertension-related events in patients treated with the VEGF pathway inhibitors axitinib or sorafenib in the AXIS trial. AXIS was a randomized phase III study of axitinib versus sorafenib in patients with metastatic RCC following failure of one prior systemic regimen. Patients with uncontrolled hypertension were excluded, but patients with hypertension controlled with antihypertensive medication were allowed to participate. Guidelines for hypertension management included adjustment or addition of antihypertensive medications and/or axitinib or sorafenib dose reductions, interruptions, or discontinuations. Treatment-emergent all-causality hypertension occurred in 145 (40.4?%) axitinib-treated patients (N--59) and 103 (29.0?%) sorafenib-treated patients (N--55), with grade 3 hypertension reported in 55 (15.3?%) and 38 (10.7?%) patients, respectively, and grade 4 hypertension reported in one (0.3?%) patient in each arm. Hypertension-related events led to axitinib dose interruptions (n--6; 12.8?%), dose reductions (n--6; 4.5?%), or discontinuations (n--; 0.3?%). Approximately 50?% of axitinib-treated patients with grade 3 or 4 hypertension continued treatment for ?9?months. Hypertension-related sequelae occurred in